查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1627881

急性腎損傷（AKI）疾病治療市場：預測（2025-2030）

Acute Kidney Injury (AKI) Disease Treatment Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 142 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

急性腎損傷（AKI）疾病治療市場預計將以 7.50% 的複合年成長率成長，從 2025 年的 20.04 億美元成長到 2030 年的 28.75 億美元。

全球急性腎損傷治療市場受到急性腎損傷發生率上升的顯著影響。國家腎臟基金會估計，美國約有 3700 萬人患有腎臟疾病。由於老化、不良飲食習慣和大量飲酒，腎臟受損的風險正在增加。對乙醯胺酚和其他藥物過量攝取、肝炎、自體免疫疾病和代謝性疾病也是導致市場爆炸的因素。此外，不斷上漲的醫療保健成本和政府改善醫療保健系統的措施預計將增加市場收益。然而，透析服務的高成本和患者對長期治療計劃的依從性低正在阻礙市場擴張。

急性腎損傷治療市場的促進因素：

  • 與文明病增加和技術進步

急性腎損傷是一種腎功能突然暫時喪失的疾病。這種情況可能是由於糖尿病或高血壓等一些潛在疾病引起的。由於人們生活方式的改變，許多疾病不斷出現。典型的例子包括糖尿病、肥胖、高血壓以及與肝臟和腎臟有關的疾病。世界衛生組織（WHO）估計，影響人的健康和生活品質的變數中有60%與人的生活方式有關。人們的健康受到加工食品、垃圾食物和不良飲食習慣的影響。此外，缺乏運動或缺乏身體活動會增加消化不良和隨後的急性腎損傷的風險。

人們對毒品、酒精、吸菸等成癮，這些都會對健康產生負面影響。缺乏身體活動和缺乏運動也會增加消化不良和相關急性腎損傷的可能性。例如，國際腎臟病學會估計全球每年發生超過 1,330 萬例急性腎損傷病例。此外，全球整體每年有 170 萬人死於急性腎損傷。在美國，大約 1% 的住院患者發生 AKI。

此外，超過 50% 的加護病房(ICU) 患者會發生 AKI，約 1% 的普通外科病例會在術後 30 天內發生 AKI。此外，根據美國國家糖尿病、消化和腎臟疾病研究所的 2023 年報告，每 1,000 名美國中有 2 人患有末期腎臟病，其中 71% 依賴透析，29% 需要接受腎臟移植。隨著腎臟疾病的流行，對準確有效治療的需求不斷增加。

急性腎損傷（AKI）疾病治療市場的地理前景：

  • 急性腎損傷治療市場分為全球五個地區。

北美急性腎損傷疾病治療市場分為美國、加拿大和墨西哥，預計在預測期內將以顯著的複合年成長率成長。由於美國糖尿病盛行率較高，急性腎損傷患者數量不斷增加。據美國疾病管制與預防中心 (CDC) 稱，AKI 是美國的重大公共衛生問題，每年影響超過 50 萬人，並導致超過 10 萬人死亡。 AKI 也與醫療保健費用增加有關，在美國，每年因 AKI 導致的住院費用估計達 100 億美元。此外，擴大採用創新治療方法，例如腎臟替代療法（RRT），其中包括血液透析機和腹膜透析。這些治療方法變得越來越廣泛和負擔得起，使更多的患者能夠獲得他們需要的治療。

此外，AKI 不同病因的盛行率將指南AKI 治療市場的未來研究和發展。例如，由於尿路阻塞是 AKI 的重要原因，藥物開發公司可能有機會專注於開發治療方法來解決這種情況，特別是患有良性前列腺增生的老年男性。

為什麼要購買這份報告？

  • 富有洞察力的分析：獲得涵蓋關鍵和新興地區的深入市場洞察，重點關注客戶細分、政府政策和社會經濟因素、消費者偏好、行業和其他子區隔。
  • 競爭格局：了解世界主要企業所採用的策略策略，並了解正確策略的市場滲透潛力。
  • 市場趨勢和促進因素：探索動態因素和關鍵市場趨勢以及它們將如何影響未來的市場發展。
  • 可行的建議：利用洞察力做出策略決策，在動態環境中釋放新的業務流和收益。
  • 受眾廣泛：對於新興企業、研究機構、顧問、中小企業和大型企業有用且具有成本效益。

它有什麼用？

產業/市場考量、商機評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、監管影響、新產品開發、競爭訊息

調查範圍

  • 2022年至2030年歷史資料與預測
  • 成長機會、挑戰、供應鏈前景、法規結構、客戶行為和趨勢分析
  • 競爭定位、策略和市場佔有率分析
  • 區域收益成長和預測分析，包括細分市場和國家
  • 公司概況（尤其是重大發展）

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現
  • 分析師觀點

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析

第5章急性腎衰竭疾病治療市場：依組成部分

  • 介紹
  • 治療
    • 藥品
    • 透析
  • 診斷
    • 尿液檢查
    • 驗血
    • 腎絲球過濾率 (GFR)
    • 影像檢查
    • 切片檢查

第6章 急性腎損傷疾病治療市場：依 RRT 型分類

  • 介紹
  • 連續的
  • 間歇性的

第7章急性腎損傷疾病治療市場：地區

  • 介紹
  • 北美洲
    • 按成分
    • 按 RRT 類型
    • 按國家/地區
  • 南美洲
    • 按成分
    • 按 RRT 類型
    • 按國家/地區
  • 歐洲
    • 按成分
    • 按 RRT 類型
    • 按國家/地區
  • 中東/非洲
    • 按成分
    • 按 RRT 類型
    • 按國家/地區
  • 亞太地區
    • 按成分
    • 按 RRT 類型
    • 按國家/地區

第8章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第9章 公司簡介

  • Exponential Biotherapies, Inc.
  • Nikkiso America, Inc.
  • Am-Pharma
  • Renalguard Solutions, Inc.
  • Angion Biomedica Corp.
  • Thrasos Therapeutics Inc.
  • Atoxbio
  • Sentien Biotechnologies, Inc
簡介目錄
Product Code: KSI061612284

The acute kidney injury (AKI) disease treatment market is predicted to grow at a CAGR of 7.50% from US$2.004 billion in 2025 to US$2.875 billion by 2030.

The global market for acute renal injury treatment is significantly influenced by the rising incidence of acute kidney damage. The National Kidney Foundation estimates that kidney illnesses impact about 37 million people in the US. Kidney injury risk has increased as a result of an aging population, poor diet, and heavy alcohol use. Acetaminophen and other drug overdoses, hepatitis, autoimmune disorders, and metabolic diseases are other causes contributing to the market's explosive expansion. Additionally, it is projected that rising healthcare costs and government measures to improve the healthcare system will boost market revenue. However, the market expansion is being hampered by the high cost of dialysis services and the low compliance from patients for long-term treatment plans.

Acute kidney injury disease treatment market drivers:

  • Increase in lifestyle-related diseases and technological advancements.

Acute kidney injury results in sudden and temporary loss of the function of the kidney. This could occur due to several underlying diseases like diabetes and high blood pressure. A slew of diseases is cropping up due to the changing lifestyles of people. Some of the prominent examples are diabetes, obesity, hypertension, and other liver or kidney-related diseases. The World Health Organisation estimates that 60% of the variables affecting a person's health and quality of life are related to their way of living. People's health is being impacted by processed and junk food as well as poor eating habits. Additionally, a lack of exercise and movement increases the risk of dyspepsia and subsequent acute renal damage.

People are developing addictions to drugs, alcohol, and smoking, all of which have detrimental effects on their health. Lack of physical movement and exercise is also increasing the likelihood of indigestion, and consequent acute kidney injuries. People are getting addicted to alcohol, smoking, and drugs which also have adverse implications for their health. For instance, the International Society of Nephrology estimates that there are over 13.3 million cases of acute renal damage each year throughout the world. Globally, acute renal damage also results in 1.7 million deaths each year. AKI is present in about 1% of hospitalized patients in the United States.

Moreover, AKI occurs in more than 50% of patients in intensive care units (ICU) and occurs within 30 days of surgery in about 1% of general surgical cases. Additionally, according to the 2023 report of the National Institute of Diabetes and Digestive and Kidney Diseases, 2 in 1000 Americans have end-stage kidney illness, with 71% relying on dialysis and 29% receiving a kidney transplant. The need for precise and effective treatment is growing along with the prevalence of renal disorders.

Acute kidney injury (AKI) disease treatment market geographical outlook:

  • The acute kidney injury disease treatment market is segmented into five regions worldwide

The North American AKI disease treatment market has been segmented into the United States, Canada, and Mexico and is estimated to grow at a significant CAGR during the forecast period. The high prevalence of diabetes in the U.S. is increasing the number of people with acute kidney injury. According to the Centers for Disease Control and Prevention (CDC), AKI is a significant public health problem in the United States, affecting over 500,000 people each year and resulting in more than 100,000 deaths. AKI is also associated with increased healthcare costs, with hospitalizations for AKI costing an estimated $10 billion annually in the US. Moreover, there is increasing adoption of innovative treatment options, such as renal replacement therapies (RRTs), which include hemodialysis and peritoneal dialysis. These treatments are becoming more widely available and affordable, allowing more patients to access the care they need.

Furthermore, the prevalence of the various causes of AKI can guide future research and development in the AKI treatment market. For instance, given that urinary tract obstruction is a significant cause of AKI, there may be an opportunity for drug developers to focus on developing therapies that address this condition, especially in older men with benign prostatic hypertrophy.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The Acute kidney injury disease treatment market is segmented and analyzed as follows:

By Component

  • Treatment
  • Drug Type
  • Isotonic Solution
  • Antibiotic
  • Others
  • Dialysis
  • Diagnosis
  • Urine Test
  • Blood Test
  • Glomerular Filtration Rate (GFR)
  • Imaging Test
  • Biopsy

By Type of RRT

  • Continuous
  • Intermittent

By Geography

  • North America

By Component

By Type of RRT

By Country

  • USA
  • Canada
  • Mexico
  • South America

By Component

By Type of RRT

By Country

  • Brazil
  • Argentina
  • Others
  • Europe

By Component

By Type of RRT

By Country

  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa

By Component

By Type of RRT

By Country

  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific

By Component

By Type of RRT

By Country

  • China
  • Japan
  • South Korea
  • India
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits for the Stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Supplier
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. ACUTE KIDNEY INJURY DISEASE TREATMENT MARKET BY COMPONENT

  • 5.1. Introduction
  • 5.2. Treatment
    • 5.2.1. Drug Type
      • 5.2.1.1. Isotonic Solution
      • 5.2.1.2. Antibiotic
      • 5.2.1.3. Others
    • 5.2.2. Dialysis
  • 5.3. Diagnosis
    • 5.3.1. Urine Test
    • 5.3.2. Blood Test
    • 5.3.3. Glomerular Filtration Rate (GFR)
    • 5.3.4. Imaging Test
    • 5.3.5. Biopsy

6. ACUTE KIDNEY INJURY DISEASE TREATMENT MARKET BY TYPE OF RRT

  • 6.1. Introduction
  • 6.2. Continuous
  • 6.3. Intermittent

7. ACUTE KIDNEY INJURY DISEASE TREATMENT MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Component
    • 7.2.2. By Type of RRT
    • 7.2.3. By Country
      • 7.2.3.1. USA
      • 7.2.3.2. Canada
      • 7.2.3.3. Mexico
  • 7.3. South America
    • 7.3.1. By Component
    • 7.3.2. By Type of RRT
    • 7.3.3. By Country
      • 7.3.3.1. Brazil
      • 7.3.3.2. Argentina
      • 7.3.3.3. Others
  • 7.4. Europe
    • 7.4.1. By Component
    • 7.4.2. By Type of RRT
    • 7.4.3. By Country
      • 7.4.3.1. Germany
      • 7.4.3.2. France
      • 7.4.3.3. United Kingdom
      • 7.4.3.4. Spain
      • 7.4.3.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. By Component
    • 7.5.2. By Type of RRT
    • 7.5.3. By Country
      • 7.5.3.1. Saudi Arabia
      • 7.5.3.2. UAE
      • 7.5.3.3. Israel
      • 7.5.3.4. Others
  • 7.6. Asia Pacific
    • 7.6.1. By Component
    • 7.6.2. By Type of RRT
    • 7.6.3. By Country
      • 7.6.3.1. China
      • 7.6.3.2. Japan
      • 7.6.3.3. South Korea
      • 7.6.3.4. India
      • 7.6.3.5. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Exponential Biotherapies, Inc.
  • 9.2. Nikkiso America, Inc.
  • 9.3. Am-Pharma
  • 9.4. Renalguard Solutions, Inc.
  • 9.5. Angion Biomedica Corp.
  • 9.6. Thrasos Therapeutics Inc.
  • 9.7. Atoxbio
  • 9.8. Sentien Biotechnologies, Inc